VivoSeq
Oncology

Fallopian Tube Carcinoma

6

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Fallopian Tube Carcinoma is an early-stage landscape with 6 programs across 6 companies. The most active players are Bristol-Myers Squibb, Boehringer Ingelheim, Avyxa. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

67/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 1A

Avyxa

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3Teva logo

Teva

1 program

ApprovedRoche logo

Roche

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

5 of 7 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody114%Vaccine114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Terminated1 · 25%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT01314105·19 enrolled
A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma
Completed·Roche logoRoche·Phase 3·NCT00434642·484 enrolled
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Terminated·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT00407407·6 enrolled
A Phase II Study of (IGFBP-2) Vaccine to Prevent Progression After Serologic Detection of Recurrent Ovarian Cancer
Not yet recruiting·UUniversity of Washington·Phase 2·NCT07495124·26 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)